39plus is a not-for-profit organisation dedicated to providing a new approach to delivering quality care to older people across the 39 postcode region. 39plus offers a range of support services for older people, people with disabilities and their carers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

HEALIVA® ACQUIRES CRITICAL CELL THERAPY MANUFACTURING ASSETS FROM B. BRAUN

Healiva | November 22, 2022

news image

Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis de...

Read More

MEDICAL

AGILENT ANNOUNCES COLLABORATION WITH APC ON REAL-TIME PROCESS MONITORING

Agilent Technologies | May 31, 2022

news image

Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd., in which the companies commit to working towards combining their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography (LC). Agilent has selected to partner with APC, a provider of innovative small molecule and large molecule process design and process development solutions. Both APC and Agilent pursue similar goals, which a...

Read More

CELL AND GENE THERAPY

AGEX THERAPEUTICS RECEIVES STOCK EXCHANGE DEFICIENCY LETTER

AgeX Therapeutics | November 24, 2021

news image

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses d...

Read More

CELL AND GENE THERAPY

INTEGRAL MOLECULAR INTRODUCES TRANSGENE PROTEIN ENGINEERING PLATFORM TO ADDRESS GENE THERAPY CHALLENGES

Integral Molecular | August 02, 2021

news image

Integral Molecular, the industry leader in membrane proteins, announces the launch of GeneCanvas, its proprietary protein engineering platform to optimize transgenes and other gene therapy elements. GeneCanvas can achieve 10 to 100 fold increases in gene activity by improving transgene protein expression, trafficking, stability, and function. These enhancements will ultimately result in better efficacy, smaller doses, and improved safety for patients. The GeneCanvas...

Read More
news image

CELL AND GENE THERAPY

HEALIVA® ACQUIRES CRITICAL CELL THERAPY MANUFACTURING ASSETS FROM B. BRAUN

Healiva | November 22, 2022

Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis de...

Read More
news image

MEDICAL

AGILENT ANNOUNCES COLLABORATION WITH APC ON REAL-TIME PROCESS MONITORING

Agilent Technologies | May 31, 2022

Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd., in which the companies commit to working towards combining their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography (LC). Agilent has selected to partner with APC, a provider of innovative small molecule and large molecule process design and process development solutions. Both APC and Agilent pursue similar goals, which a...

Read More
news image

CELL AND GENE THERAPY

AGEX THERAPEUTICS RECEIVES STOCK EXCHANGE DEFICIENCY LETTER

AgeX Therapeutics | November 24, 2021

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses d...

Read More
news image

CELL AND GENE THERAPY

INTEGRAL MOLECULAR INTRODUCES TRANSGENE PROTEIN ENGINEERING PLATFORM TO ADDRESS GENE THERAPY CHALLENGES

Integral Molecular | August 02, 2021

Integral Molecular, the industry leader in membrane proteins, announces the launch of GeneCanvas, its proprietary protein engineering platform to optimize transgenes and other gene therapy elements. GeneCanvas can achieve 10 to 100 fold increases in gene activity by improving transgene protein expression, trafficking, stability, and function. These enhancements will ultimately result in better efficacy, smaller doses, and improved safety for patients. The GeneCanvas...

Read More